Circularly permutated, interaction-activated proteins
View Patent ↗Interaction-activated circularly permutated proteins are disclosed that depend for their functional reassembly into the parent protein on the interaction of heterologous polypeptides or other molecules which have been genetically or chemically conjugated to the break-point termini of engineered enzymes. In addition, methods are provided for identifying circularly permutated marker proteins that will optimally reassemble into a functional parent protein, and which are dependent on the association of heterologous interactor domains. The invention is exemplified by circular permutations of a Class A β-lactamase (TEM-1 of E. coli ). Circularly permutated marker proteins that comprise molecular interaction-dependent enzymes particularly find use in (1) cell-based sensors for activation or inhibition of metabolic or signal transduction pathways for high-efficiency, (2) high-throughput screening for agonists/antagonists of the target pathway and in high-throughput mapping of pair-wise protein-protein interactions within and between the proteomes of cells, tissues, and pathogenic organisms, and in (3) cell-based screens for high-throughput selection of inhibitors of any protein-protein interaction.
1. A polypeptide consisting essentially of:
a circularly permutated TEM-1 β-lactamase protein, joined at the original amino and carboxy termini, having an N-terminal portion with a new C-terminus and a C-terminal portion with a new N-terminus, a first interactor domain, and a second interactor domain;
wherein the first interactor domain is fused through the new N-terminus of the C-terminal portion, and the second interactor domain is fused through the new C-terminus of the N-terminal portion; and
wherein the new N-terminus and the new C-terminus are located within a solvent exposed loop between amino acid residues Thr 195 and Ala 202 (residues 170-177 of SEQ ID NO:2); and
wherein the first interactor domain is selected from the group consisting of an antibody, an antigen, a first monomer of a hetero-dimerizing helix, a second monomer of a hetero-dimerizing helix, a receptor, a member of an expressed sequence library, and a member of a constrained peptide library; and
wherein the second interactor domain is selected from the group consisting of an antibody, an antigen, a first monomer of a hetero-dimerizing helix, a second monomer of a hetero-dimerizing helix, a receptor, a member of an expressed sequence library, and a member of a constrained peptide library;
wherein the circularly permutated TEM-1 β-lactamase protein is functionally reconstituted only upon binding of said first interactor domain to said second interactor domain, optionally through a ligand.
2. The polypeptide of claim 1 , wherein the new C-terminus of the N-terminal portion is Glu 197 (residue 172 of SEQ ID NO:2) and the new N-terminus of the C-terminal portion is Leu 198 (residue 173 of SEQ ID NO:2).
3. The polypeptide of claim 1 , wherein said first interactor domain and said second interactor domain bind to a single ligand, and
wherein said circularly permutated TEM-1 β-lactamase protein is functionally reconstituted only upon binding of said first interactor domain and said second interactor domain to said ligand.
4. The polypeptide of claim 3 , wherein said ligand is comprised of an antigen fused to a second monomer of a hetero-dimerizing helix protein, said first interactor domain is an antibody, and said second interactor domain is a first monomer of a hetero-dimerizing helix, or
wherein said ligand is comprised of an antibody fused to a second monomer of a hetero-dimerizing helix protein, said first interactor domain is an antigen and said second interactor domain is a first monomer of a hetero-dimerizing helix and
wherein the first monomer of the hetero-dimerizing helix specifically binds to the second monomer of the hetero-dimerizing helix protein and the antibody specifically binds to the antigen.
5. The polypeptide of claim 4 , wherein the antibody of the first interactor domain, or the antibody of the ligand comprising an antibody fused to a second monomer of the hetero-dimerizing helix protein, is a single chain antibody fragment (scFv).
6. The polypeptide of claim 1 , wherein the first interactor domain is fused through a first flexible polypeptide linker to the circularly permutated β-lactamase protein through the N-terminal break-point, and the second interactor domain is fused through a second flexible polypeptide linker to the circularly permutated β-lactamase protein through the C-terminal break-point.
7. The polypeptide of claim 6 , wherein said first polypeptide linker is 3-30 amino acids in length; and wherein said second polypeptide linker is 3-30 amino acids in length.